J&J Launches Innovation Challenge In China

Johnson & Johnson Innovation together with Johnson & Johnson Medical Shanghai Ltd. has announced the launch of the China Digital Technologies of Tomorrow QuickFire Challenge with the aim to identify and accelerate cutting-edge, early-stage digital innovations looking to bring forward potential transformative technologies for the patients who need them most. The competition is open to visionaries from around the world with novel, medical device concepts or products for perioperative treatment solutions, diagnostics and emerging technologies with the potential to transform patient care in atrial fibrillation (AFIB), neurovascular treatment, general and orthopedic surgery. The innovator(s) with the best potential solution(s) in areas such as artificial intelligence (AI), 3D-printing (3DP), IoT, 5G and beyond can be awarded grant funding from a total of up to US$100,000; one year of residency at JLABS @ Shanghai, including a workstation and access to the JLABS ecosystem; and mentorship from experts at the Johnson & Johnson Family of Companies. "We are interested in a wide range of potential applications from remote surgery to early warnings of disease and beyond," said Sharon Chan, Head of JLABS @ Shanghai. "We have 13 JLABS worldwide, with JLABS @ Shanghai being the largest globally, as well as the first in Asia Pacific. We are looking forward to welcoming the awardees of the China Digital Technologies of Tomorrow QuickFire Challenge to be part of our dynamic community of innovators and to supporting them on their innovation journeys." The QuickFire Challenge platform was developed with the aim to empower and enable potential ground-breaking science and health solutions by encouraging students, entrepreneurs, researchers and start-up companies to tackle some of the world's most challenging problems in healthcare. "China remains a critical market and has become the 'development + innovation' dual engine for Johnson & Johnson's business portfolio. We have chosen to launch this challenge in China because the region's digital technology and innovation is making rapid progress that can potentially benefit China and the world. Through our joint efforts, we are actively engaging with the Chinese healthcare innovation ecosystem and technology community with the aim to bring together disruptive solutions to advance health for humanity," said Will Song, China Chairman, Johnson & Johnson.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!